May 26, 2020
Novartis Pharma on May 25 rolled out its hoped-to-be big-seller VEGF inhibitor Beovu (brolucizumab) in Japan for the treatment of age-related macular degeneration (AMD). The drug is indicated for the treatment of AMD with subfoveal choroidal neovascularization. Beovu carries a...read more